Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Eli Lilly & Co. (LLY) were down more than 2% Friday after the pharmaceutical company announced that the Food and Drug Administration (FDA) wants more information about its experimental Alzheimer's treatment, donanemab, which will delay its release.

Eli Lilly's Alzheimer's Drug Release Delayed for FDA Investigation

Advanced Micro Devices

Constellation Energy Corp

NVIDIA

The S&P 500 soared to new all-time highs on reassuring comments regarding potential interest rate declines. SPDR S&P 500 ETF Trust (SPY), the proxy version of the S&P 500 Index, has risen 8.3% so far this year.

S&P 500 Soars to New Highs: 5 Best Stocks YTD

The FDA has delayed a decision on whether it will approve donanemab, Eli Lilly's closely watched new Alzheimer's drug, despite promising study results that showed it could significantly slow cognitive and functional decline in early-symptomatic Alzheimer's patients, the pharmaceutical company announced Friday.

What Is Donanemab? Eli Lilly's Alzheimer's Drug Gets Delayed Decision From FDA

The timing of the agency's expected action on the donanemab drug would be postponed beyond the first quarter, the company said.

Eli Lilly Alzheimer's Drug Delayed as FDA Plans Advisory Panel Meeting

Eli Lilly and Co (NYSE:LLY) stock is slipping today, after the U.S. Food & Drug Administration (FDA) delayed approving the drugmaker's Alzheimer's drug, donanemab, which was expected to be approved this month, and called for an advisory panel.

Eli Lilly Stock Slips on FDA Approval Delay

The FDA plans to call a last-minute meeting of its outside advisors to further review the Eli Lilly Alzheimer's treatment's safety and efficacy.

Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move

The FDA plans to hold a special committee to discuss the Phase 3 trial results of donanemab.

Eli Lilly Says FDA Delays Decision on Alzheimer's Drug

The FDA will hold an advisory panel for Eli Lilly's Alzheimer drug donanemab, delaying approval beyond the first quarter. Lilly stock fell.

FDA Delays Decision On Eli Lilly's Alzheimer Drug

The U.S. Food and Drug Administration has delayed a decision on whether to approve Eli Lilly's experimental treatment for early Alzheimer's disease and will hold a meeting of outside experts to discuss its safety and efficacy, the company said.

US FDA delays Lilly Alzheimer's drug decision, calls for advisory panel

INDIANAPOLIS , March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and safety of donanemab in early symptomatic Alzheimer's disease.  The FDA has informed Lilly it wants to further understand topics related to evaluating the safety and efficacy of donanemab, including the safety results in donanemab-treated patients and the efficacy implications of the unique trial design of the TRAILBLAZER-ALZ 2 study, including its limited-duration dosing regimen that allowed patients to complete treatment based on an assessment of amyloid plaque and the inclusion of participants based on tau levels.

U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab

Successful investor Mario Gabelli attained billionaire status primarily by investing his and his client's money. He became well-known in the 1980s for making successful picks in media and telecom sectors, and was named Morningstar's “Portfolio Manager of the Year” in 1997 and received the “Money Manager of the Year” award from Institutional Investor in 2011.

3 Stocks Mario Gabelli Is Betting on Big

Lilly (LLY) reported earnings 30 days ago. What's next for the stock?

Lilly (LLY) Up 7.5% Since Last Earnings Report: Can It Continue?

Eli Lilly said on Thursday it has found bacteria and high levels of impurities in products claiming to be compounded versions of tirzepatide, the active ingredient in its popular diabetes drug Mounjaro and weight loss treatment Zepbound.

Lilly finds bacteria, other impurities in Mounjaro, Zepbound knockoffs

Two new films draw attention to the importance of treating obesity as a disease and the appropriate use of anti-obesity medications INDIANAPOLIS , March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to reinforce its commitment to discovering and making medicines that give people a chance at better health.

Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care

Novo Nordisk

Novo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a new weight loss drug.

Novo Nordisk shares jump 5% on promising weight loss trial results; Eli Lilly dips

Eli Lilly and Co (NYSE:LLY ) Cowen's 44th Annual Health Care Conference March 6, 2024 9:10 AM ET Company Participants Anat Ashkenazi - EVP & CFO Andrew Adams - Vice President of New Therapeutic Modalities & Scientific Leader Conference Call Participants Stephen Scala - TD Cowen Anat Ashkenazi Thank you all for coming to listen to the Lilly's story this morning, and hope I'm sure you've been tracking us for a while. And you've seen what we've shared on the earnings call, the great progress we've had last year and that we're continuing to have robust top-line growth driven by our key growth products.

Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript)

Taiwan Semiconductor Manufacturing

Seriously, how much longer before Nvidia (NASDAQ: NVDA ) overtakes Microsoft (NASDAQ: MSFT ) as the most valuable company in the world? The chipmaker just surpassed Saudi Aramco to become the third-most richly valued company at $2.2 trillion.

Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise

INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego. The presentations will include new preclinical data for a fully human monoclonal anti-Nectin-4 antibody conjugated to a novel topoisomerase I inhibitor and a highly potent and orally administered inhibitor of KRAS G12D that is selective against wild-type KRAS.

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting

Eli Lilly and Novo Nordisk stock each rose over 50% in 2023 thanks to their diabetes treatments. Industry research suggests the diabetes market will continue to grow for decades to come.

Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why

Viking Therapeutics

Anti-obesity medicines are currently a tremendously lucrative market. Viking Therapeutics is ascendant after publishing strong phase 2 data.

Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly

Amgen

BioNTech SE

Much like Big Tech companies ride the AI hype, pharma stocks are counting on valuation boosts from big drug hits and FDA approvals. This anticipation, however, brings to light the importance of discerning which pharma stocks to sell, as not all will sustain their high-growth promises, potentially generating double-digit profits in the short term.

It's Time! 3 Dodgy Pharma Stocks to Sell in February

Weight control drugs like Mounjaro and Zepbound drove 28% sales growth for Lilly last quarter. Bank of America says Lilly has other drugs in its pipeline that could grow Lilly even more.

1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $1000. Is It a Buy Around $782?

The approval of Zepbound as a weight-loss drug is proving to be a game changer for Eli Lilly. While the valuation is a bit pricey, interested investors might want to wait for a better entry point.

This Is the Biggest Company Not in the "Magnificent Seven" -- but It Deserves to Be

Blockbuster drugs can be disproportionately beneficial for biopharmas. Novo Nordisk is already squeezing a lot of cash out of semaglutide.

Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly

Eli Lilly's prospects look solid thanks to a key medicine, a solid lineup, and a deep pipeline. Viking Therapeutics' shares could skyrocket (again) on positive clinical developments.

News for Eli Lilly Stock (LLY)